Please use this identifier to cite or link to this item: https://dspace.uzhnu.edu.ua/jspui/handle/lib/44534
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSmolanka, V.-
dc.contributor.authorСмоланка, Володимир Іванович-
dc.contributor.authorO’Connor, Paul-
dc.contributor.authorWolinsky, Jerry S.-
dc.contributor.authorConfavreux, Christian-
dc.contributor.authorComi, Giancarlo-
dc.contributor.authorKappos, Ludwig-
dc.contributor.authorOlsson, Tomas P.-
dc.contributor.authorBenzerdjeb, Hadj-
dc.contributor.authorTruffinet, Philippe-
dc.contributor.authorWang, Lin-
dc.contributor.authorMiller, Aaron-
dc.contributor.authorFreedman, Mark S.-
dc.contributor.authorTeriflunomide Multiple Sclerosis Oral (TEMSO) Trial Groupen
dc.date.accessioned2022-09-28T08:02:22Z-
dc.date.available2022-09-28T08:02:22Z-
dc.date.issued2011-
dc.identifier.citationO'Connor P. and others Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis / P. O'Connor, J. S. Wolinsky, C. Confavreux et al. // The New England Journal of Medicine. – Massachusetts Medical Society, 2011. Vol. 365. – P. 1293-1303.uk
dc.identifier.urihttps://dspace.uzhnu.edu.ua/jspui/handle/lib/44534-
dc.description.abstractTeriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis. Teriflunomide significantly reduced relapse rates, disability progression (at the higher dose), and MRI evidence of disease activity, as compared with placebo. (Funded by Sanofi-Aventis; TEMSO ClinicalTrials.gov number, NCT00134563.)uk
dc.language.isoenuk
dc.publisherMassachusetts Medical Societyuk
dc.titleRandomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosisuk
dc.typeTextuk
dc.pubTypeСтаттяuk
Appears in Collections:Наукові публікації кафедри неврології, нейрохірургії та психіатрії

Files in This Item:
File Description SizeFormat 
Randomized Trial of Oral Teriflunomide.pdf598.26 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.